GlassScriptPhysician profile
Kenneth D Nahum
NPI 1922079904
$4,802.96
in general payments reported to CMS, 2019-2025
53 companies · $1,152 in 2025
The $1,152 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $318 · 2021: $259 · 2022: $810 · 2023: $1,106 · 2024: $755 · 2025: $1,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,462 · Education: $551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,461.73 |
| Education | $551.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $664.53 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $552.37 | 2020-2025 | Opdivo, Opdualag, Krazati |
| Gilead Sciences, INC. | $511.83 | 2019-2025 | Trodelvy |
| Pfizer INC. | $305.33 | 2021-2025 | |
| Daiichi Sankyo INC. | $288.87 | 2020-2025 | Enhertu, Datroway |
| Abbvie INC. | $263.73 | 2023-2025 | |
| Janssen Biotech, INC. | $179.52 | 2021-2024 | Erleada, Tecvayli, Talvey |
| Eisai INC. | $157.41 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $147.43 | 2020-2024 | Keytruda, Welireg, Lynparza |
| Astellas Pharma US INC | $120.59 | 2022-2025 | Vyloy, Xospata |
| Kite Pharma, INC. | $115.19 | 2022-2025 | Yescarta |
| Glaxosmithkline, LLC. | $113.00 | 2021-2025 | Jemperli, Zejula, Ojjaara |
| Incyte Corporation | $99.95 | 2019 | |
| Seagen INC. | $93.99 | 2019-2023 | Adcetris |
| Revance Therapeutics, INC. | $92.18 | 2025 | Daxxify |
Show all 51 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Nahum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.